AR067954A1 - Compuestos de carbazol - Google Patents
Compuestos de carbazolInfo
- Publication number
- AR067954A1 AR067954A1 ARP080103573A ARP080103573A AR067954A1 AR 067954 A1 AR067954 A1 AR 067954A1 AR P080103573 A ARP080103573 A AR P080103573A AR P080103573 A ARP080103573 A AR P080103573A AR 067954 A1 AR067954 A1 AR 067954A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heteroaryl
- heterocycloalkyl
- Prior art date
Links
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical class C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 26
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 125000001118 alkylidene group Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- -1 C 2- alkenyl 6 Chemical group 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
Procesos y composiciones farmacéuticas que incluyen los compuestos. Son utiles en tratamiento, en particular en el tratamiento del dolor. Reivindicacion 1: Un compuesto de formula (1), una sal aceptable desde el punto de vista farmacéutico de la misma, diastereomero, enantiomero, o una mezcla de los mismos donde Y se selecciona de los compuestos de formulas (2); R1 se selecciona de -H, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-4, -C(=O)-NR14R15, -S(=O)2NR14R15, -S(=O)2-alquilo C1-6, -S(=O)2-arilo C6-10, -S(=O)2-heteroarilo C2-5, -C(=O)-alquilo C1-6, -C(=O)-O-alquilo C1-6, aril C6-10-alquilo C1-4 y heteroaril C2-5-alquilo C1-4, donde dicho alquilo C1-6, alquenilo C2-6, -S(=O)2-alquilo C1-6, -S(=O)2-arilo C6-10, -S(=O)2-heteroarilo C2-5, -C(=O)-alquilo C1-6, aril C6-10-alquilo C1-4 y heteroaril C2-5-alquilo C1-4 usado para definir R1 se sustituyen opcionalmente con uno o más grupos seleccionados de -OR, R, -CO2H, -CO2-R, -SO2-R, halogeno, -NO2, -OH, -NH2, -NHR, -CN, -C(=O)-NH2, -C(O)-NR2 y -C(=O)-NHR; R2 se selecciona de heterocicloalquilo C3-6, heterocicloalquilo C3-6-alquiIo C1-4, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-4, alquilo C1-6, aIquenilo C2-6, arilo C6-10, aril C6-10-alquilo C1-4, heteroarilo C2-6, heteroaril C2-6-alquilo C1-4, -C(=O)-alquilo C1-6, -C(=O)-cicloalquilo C3-6 y -C(=NH)-alquilo C1-6, donde dicho heterocicloalquilo C3-6, heterocicloalquil C3-6-alquilo C1-4, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-4, alquilo C1-6, alquenilo C2-6, arilo C6-10, aril C6-10-alquilo C1-4, heteroarilo C2-6, heteroaril C2-6-alquilo C1-4, -C(=O)-alquilo C1-6, -C(=O)-cicloalquilo C3-6 y -C(=NH)-alquilo C1-6 utilizado para definir R2 están opcionalmente sustituidos con uno o más grupos seleccionados de -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogeno, -OH, -NH2, -NHR, -CN, -C(=O)-NH2 y -C(=O)-NHR; R3 y R4 se seleccionan de manera independiente de -H, cicloalquilo C3-6, heterocicloalquilo C3-6, heteroarilo C2-5, arilo C6-10, alquilo C1-6, alcoxi C1-6, amino, alquilamino C1-6, dialquilamino C1-6, -C(=O)-alquilo C1-6, -C(=O)-O-alquilo C1-6, -C(=O)-cicloalquilo C3-6, -C(=O)-NR14R15 y -S(=O)2-NR14R15, donde dicho cicloalquilo C3-6, heterocicloalquilo C3-6, heteroarilo C2-5, arilo C6-10, alquilo C1-6, alcoxi C1-6, alquilamino C1-6, dialquilamino C1-6, -C(=O)-alquilo C1-6, -C(=O)-O-alquilo C1-6 y -C(=O)-cicloalquilo C3-6 utilizado para definir R3 y R4 están opcionalmente sustituidos con uno o más grupos seleccionados de -OR, R, NO2, -CO2H, -CO2-R, -SO2-R, halogeno, -OH, -NH2, -NHR, -C(=O)-NH2, -CN. -C(=O)-NR2 y -C(=O)-NHR; R5 se selecciona de -H, alquilo C1-6, y cicloalquilo C3-6; R6 se selecciona de manera independiente de -H, -CN, -NO2, alcoxi C1-6, halogeno, alquilo C1-6, -OH, -NH2, -NHC(=O)R12 y -C(=O)NR12R13; R12 y R13 se seleccionan de manera independiente de -H, alquilo C1-6, alcoxi C1-6, heterocicloalquilo C3-6, cicloalquil C3-6-alquilo C1-4, y cicloalquilo C3-6 donde dicho alquilo C1-6, alcoxi C1-6, heterocicloalquilo C3-6, cicloalquil C3-6-alquilo C1-4, y cicloalquilo C3-6 utilizado para definir R12 y R13 están opcionalmente sustituidos con uno o más halogenos u -OH; R14 y R15 se seleccionan de manera independiente de -H, alquilo C1-6, arilo C6-10, aril C6-10-alquilo C1-4, heterociclilo C2-5, heterociclil C2-5-alquilo C1-4, alquenilo C2-6, cicloalquilo C3-6, y cicloalquil C3-6-alquilo C1-4, N,N-di(alquil C1-4)amido-alquilo C1-6, hidroxi-alquilo C1-6 y alcoxi C1-6-alquilo C1-6 que están opcionalmente sustituidos con uno o más grupos seleccionados de halogeno, -OH, -CN, -NH2 y metoxi; Q se selecciona independientemente de alquileno C1-6, alquilideno C1-6 y el resto de formula (3), donde dicho alquileno C1-6 y alquilideno C1-6 están opcionalmente sustituidos con uno o más grupos seleccionados de -OR, -R, hidroxi-alquilo C1-6, NO2, -CO2H, -CO2-R, -SO2-R, halogeno, -OH, -NH2, -NHR, -C(=O)-NH2, -CN, -C(=O)-NR2 y -C(=O)-NHR; X se seleccione de -OH, halogeno u -OR; n se selecciona independientemente de 1, 2 y 3; p, q y m se seleccionan de manera independiente de 0, 1, 2 y 3; y R es independientemente alquilo C1-6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95647807P | 2007-08-17 | 2007-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067954A1 true AR067954A1 (es) | 2009-10-28 |
Family
ID=39930420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103573A AR067954A1 (es) | 2007-08-17 | 2008-08-15 | Compuestos de carbazol |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20090062251A1 (es) |
| EP (1) | EP2190838A1 (es) |
| JP (1) | JP2010536737A (es) |
| KR (1) | KR20100061491A (es) |
| CN (1) | CN101827838A (es) |
| AR (1) | AR067954A1 (es) |
| AU (1) | AU2008290325A1 (es) |
| BR (1) | BRPI0815493A2 (es) |
| CA (1) | CA2696697A1 (es) |
| CL (1) | CL2008002431A1 (es) |
| MX (1) | MX2010001574A (es) |
| PE (1) | PE20090598A1 (es) |
| RU (1) | RU2010102992A (es) |
| TW (1) | TW200908963A (es) |
| UY (1) | UY31294A1 (es) |
| WO (1) | WO2009024819A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090062251A1 (en) * | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| US8383615B2 (en) * | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
| IN2012DN05122A (es) * | 2009-12-11 | 2015-10-23 | Bayer Ip Gmbh | |
| JP5841361B2 (ja) * | 2011-06-29 | 2016-01-13 | 壽製薬株式会社 | 三環性化合物及びそれを含有する医薬組成物 |
| JP6106452B2 (ja) * | 2012-12-05 | 2017-03-29 | 公益財団法人微生物化学研究会 | 化合物、及びその製造方法、並びにリン酸オセルタミビルの製造方法 |
| US9714234B2 (en) | 2013-06-25 | 2017-07-25 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds |
| AR096721A1 (es) | 2013-06-25 | 2016-01-27 | Bristol Myers Squibb Co | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos |
| GB201312768D0 (en) * | 2013-07-17 | 2013-08-28 | Ge Healthcare Ltd | Work-up procedure |
| CA2965517C (en) | 2014-10-24 | 2023-05-02 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhibitors |
| WO2016065222A1 (en) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Tricyclic atropisomer compounds |
| PH12017500724B1 (en) | 2014-10-24 | 2023-07-05 | Bristol Myers Squibb Co | Carbazole derivatives |
| EP4110463A1 (en) * | 2020-02-24 | 2023-01-04 | Galyan Bio, Inc. | Indole compounds for the treatment of neurodegenerative diseases |
| EP4140481A1 (en) * | 2021-08-26 | 2023-03-01 | Galyan Bio, Inc. | Protein-oligomer binding agents and therapeutic uses thereof |
| WO2023025915A1 (en) * | 2021-08-25 | 2023-03-02 | Galyan Bio, Inc. | Protein-oligomer binding agents and therapeutic uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4009181A (en) * | 1973-01-22 | 1977-02-22 | Hoffmann-La Roche Inc. | Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof |
| JP2005527586A (ja) * | 2002-04-05 | 2005-09-15 | メルク エンド カムパニー インコーポレーテッド | 置換アリールアミド |
| CN102030750A (zh) * | 2005-03-22 | 2011-04-27 | 阿斯利康(瑞典)有限公司 | 用作CB1受体配体的新四氢-1H-吡啶并[4,3-b]吲哚衍生物 |
| US20090062251A1 (en) * | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
-
2008
- 2008-08-12 US US12/189,945 patent/US20090062251A1/en not_active Abandoned
- 2008-08-13 TW TW097130806A patent/TW200908963A/zh unknown
- 2008-08-15 AU AU2008290325A patent/AU2008290325A1/en not_active Abandoned
- 2008-08-15 BR BRPI0815493-7A2A patent/BRPI0815493A2/pt not_active IP Right Cessation
- 2008-08-15 AR ARP080103573A patent/AR067954A1/es unknown
- 2008-08-15 EP EP08788684A patent/EP2190838A1/en not_active Withdrawn
- 2008-08-15 KR KR1020107005774A patent/KR20100061491A/ko not_active Withdrawn
- 2008-08-15 MX MX2010001574A patent/MX2010001574A/es not_active Application Discontinuation
- 2008-08-15 PE PE2008001393A patent/PE20090598A1/es not_active Application Discontinuation
- 2008-08-15 UY UY31294A patent/UY31294A1/es unknown
- 2008-08-15 CA CA2696697A patent/CA2696697A1/en not_active Abandoned
- 2008-08-15 WO PCT/GB2008/050713 patent/WO2009024819A1/en not_active Ceased
- 2008-08-15 RU RU2010102992/04A patent/RU2010102992A/ru not_active Application Discontinuation
- 2008-08-15 JP JP2010520636A patent/JP2010536737A/ja active Pending
- 2008-08-15 CN CN200880112253A patent/CN101827838A/zh active Pending
- 2008-08-15 US US12/673,617 patent/US20110160180A1/en not_active Abandoned
- 2008-08-18 CL CL2008002431A patent/CL2008002431A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200908963A (en) | 2009-03-01 |
| US20090062251A1 (en) | 2009-03-05 |
| EP2190838A1 (en) | 2010-06-02 |
| PE20090598A1 (es) | 2009-06-10 |
| MX2010001574A (es) | 2010-03-15 |
| AU2008290325A1 (en) | 2009-02-26 |
| CA2696697A1 (en) | 2009-02-26 |
| UY31294A1 (es) | 2009-03-31 |
| JP2010536737A (ja) | 2010-12-02 |
| CL2008002431A1 (es) | 2009-06-05 |
| CN101827838A (zh) | 2010-09-08 |
| US20110160180A1 (en) | 2011-06-30 |
| RU2010102992A (ru) | 2011-09-27 |
| KR20100061491A (ko) | 2010-06-07 |
| WO2009024819A1 (en) | 2009-02-26 |
| BRPI0815493A2 (pt) | 2015-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067954A1 (es) | Compuestos de carbazol | |
| AR053699A1 (es) | Derivados de tetrahidro-1h-pirido[4,3-b]indoles como ligandos de receptores cb1 | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR068054A1 (es) | Compuestos de pirrolopirimidina | |
| ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| FI3774791T3 (fi) | Heterosyklisiä yhdisteitä immunomodulaattoreina | |
| AR036365A1 (es) | 1,8-naftiridin-4(1h)-onas alquin-aril sustituidas y composiciones farmaceuticas que las contienen | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR045260A1 (es) | Compuestos que contienen imidazo-oxima sustituidos | |
| PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR058065A1 (es) | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. | |
| AR069494A1 (es) | Derivados de acidos fosfonicos | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| HRP20050641A2 (en) | New carboxylic acids and the esters thereof, pharmaceutical compositions containing these compounds and processes for the preparation thereof | |
| AR060729A1 (es) | Compuestos agonistas de los receptores muscarinicos | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR049898A1 (es) | Compuestos aminocarbonil fenilo sustituidos, composicion farmaceutica,uso y proceso para prepararlos | |
| AR060472A1 (es) | Derivados de sulfonil-benzimidazoles moduladores o ligandos de receptores cb1, composiciones farmaceuticas que los contienen, metodo de preparacion y usos en terapia, particularmente para alivio del dolor. | |
| CO5680443A2 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos | |
| AR041546A1 (es) | Agentes antibacterianos de tetrahidroquiolina triciclicos | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |